Telix Pharmaceuticals announced that the IPAX-2 Phase 1 trial of TLX101-Tx for newly diagnosed glioblastoma has completed patient enrolment with no dose-limiting toxicities observed, even at the highest dose tested. This trial evaluates TLX101-Tx combined with standard post-surgical treatments and aims to confirm the maximum tolerated dose. TLX101-Tx is also being tested in a pivotal Phase 3 trial for recurrent glioblastoma, marking the first radiopharmaceutical to reach this stage for the disease. The positive safety profile supports continued development of this targeted therapy for a cancer with limited treatment options and poor prognosis.
Micron Technology's stock dropped nearly 13% over two days, marking its worst decline since April 2025, driven by overheated technical indicators and broader semiconductor sector weakness. Despite the sharp pullback, the stock remains significantly a...
Hyperscale Data, an AI data center company focused on Bitcoin, announced monthly cash dividends of $0.2708333 per share for its 13.00% Series D preferred stock and $0.20833 per share for its 10.00% Series E preferred stock. The dividends will be paid...
Vishay Intertechnology announced a quarterly dividend of $0.10 per share for both common and Class B common stock. The dividend will be paid on June 29, 2026, to shareholders recorded by June 18, 2026. Future dividends will depend on board approval. ...
Valley National Bancorp announced its regular quarterly dividends for preferred and common stockholders, payable in late June and early July 2026. The preferred stock dividends vary by series, with payments ranging from approximately $0.48 to $0.52 p...
Cytokinetics granted stock options for 20,807 shares and 13,793 restricted stock units (RSUs) to eight new employees who started in April and May 2026. The RSUs vest over three years, while the stock options vest over four years with an exercise pric...
